Table 1. Overview of the simulation scenarios.

	Strong activation	Weak activation	No activation
Cont. TKI and cont. IFNα
w/o SRD	Figure 3 (+)	Figure 3 (+)	Figure 3 (+)
with SRD	Figure 4 (+)	Figure 4 (!)	Figure 4 (−)
Cont. TKI and pulsed IFNα
w/o SRD	Figure 5 (+)	Figure 5 (+)	Figure 5 (+)
with SRD	Supp. Figure 4 (+)	Supp. Figure 4 (+)	Supp. Figure 4 (+)
Pulsed TKI and pulsed IFNα
w/o SRD	Figure 6A–C (−)	Figure 6D–F (!)	Figure 6G–I (!)
with SRD	Supp. Fig. 5A–C (−)	Supp. Fig. 5D–F (!)	Supp. Fig. 5G–I (!)
Pulsed TKI and cont. IFNα
w/o SRD	Supp. Figure 7 (−)	Supp. Figure 7 (−)	Supp. Figure 7 (−)
with SRD	Supp. Figure 6 (!)	Supp. Figure 6 (−)	Supp. Figure 6 (−)

Abbreviations: cont.=continuous; IFNα=interferon-α, SRD=self-renewal deficit; Supp.=Supplementary; TKI=tyrosine kinase inhibitor. w/o (or with) SRD refers to the simulation scenarios in which the additional IFNα-mediated SRD of normal and leukaemic cells was taken into account (or not, respectively). Symbols in parentheses indicate whether the simulation scenarios predict beneficial or neutral treatment effects (+), therapy failure (−), or scenarios in which temporary, high values of BCR–ABL/ABL ratios have to be expected (!).